| Literature DB >> 24167726 |
Guem Hee Baek1, Haili Cheng, Vitnary Choe, Xin Bao, Jia Shao, Shiwen Luo, Hai Rao.
Abstract
Cdc48 (also called VCP and p97) is an abundant protein that plays essential regulatory functions in a broad array of cellular processes. Working with various cofactors, Cdc48 utilizes its ATPase activity to promote the assembly and disassembly of protein complexes. Here, we review key biological functions and regulation of Cdc48 in ubiquitin-related events. Given the broad employment of Cdc48 in cell biology and its intimate ties to human diseases (e.g., amyotrophic lateral sclerosis), studies of Cdc48 will bring significant insights into the mechanism and function of ubiquitin in health and diseases.Entities:
Year: 2013 PMID: 24167726 PMCID: PMC3791797 DOI: 10.1155/2013/183421
Source DB: PubMed Journal: J Amino Acids ISSN: 2090-0112
Figure 1Number of papers on Cdc48 published since 1982. Key words “Cdc48, VCP, and p97” were used to search PUBMED for papers on Cdc48 from 1982 to 2012.
Figure 2Structural and functional organization of Cdc48. (a) Cdc48 consists of the conserved N-terminal domain (N), two conserved AAA ATPase domains (D1 and D2), and the C-terminal domain (C). The numbers refer to the amino acid positions within the protein in yeast and human Cdc48, respectively. Cofactors associated with the N and C domains are listed. Yeast proteins, nearly all of which have human homologues, are highlighted in italics. (b) The active Cdc48 is a ring-shaped hexamer. (c) Cdc48 and its cofactors assemble in a Swiss army knife manner.
Functions and substrates of some Cdc48 cofactors.
| Cofactor | Function | Substrates |
|---|---|---|
| Ufd1-Npl4 | ERAD, cell cycle control, nuclear transport, DNA repair, transcription, ribosome-associated degradation, essential for cell growth, clearance of damaged mitochondria |
|
|
| ||
| Ufd2/E4B | Ubiquitin chain synthesis, cell cycle control, ERAD, cardiac development, and nervous system maintenance |
|
|
| ||
| Ufd3/PLAA | Ubiquitin homeostasis, ribophagy, tRNA import to mitochondria, DNA repair, multivesicular body sorting |
|
|
| ||
| Vms1/ANKZF-1 | ERAD, mitochondria stress response |
|
|
| ||
| Ubx1/p47/Shp1 | Autophagy, nuclear envelop formation, ER biogenesis, Golgi assembly |
|
|
| ||
| Ubx2 | ERAD, lipid droplet maintenance |
|
|
| ||
| Ubx3 |
|
|
|
| ||
| Ubx4 | ERAD, DNA repair |
|
|
| ||
| Ubx5 | Links Cdc48 to CRL E3 ligases |
|
|
| ||
| Ubx6 |
|
|
|
| ||
| Ubx7 |
|
|
|
| ||
| FAF1 | ERAD, proapoptosis factor | CD3 |
|
| ||
| Ataxin-3 | Ubiquitin chain editing, ERAD, stress response | TCR |
Substrates of Cdc48 cofactors in yeast S. cerevisiae are indicated in bold.
Mutations and defects in Cdc48-related diseases.
| Mutation | Domain located | Disease | Biochemical defects |
|---|---|---|---|
| R93C | N domain | IBMPFD | Impaired degradation of ERAD substrates (e.g., CFTR, tyrosinase) [ |
|
| |||
| R95G | N domain | IBMPFD | Increased bindings to Ufd1, Npl4, p47, Ataxin 3, and ubiquitylated substrates; reduced bindings to Ufd2, CAV1, and UBXD1; little effects on the bindings to Hrd1, Png1 [ |
|
| |||
| P137L | N domain | IBMPFD | Abolished bindings to Ufd1, Npl4, and p47, but still bind gp78 [ |
|
| |||
| R155H | N domain | IBMPFD and ALS | Increased bindings to Ufd1, Npl4, p47, Ataxin 3, and ubiquitylated substrates; reduced bindings to Ufd2, CAV1, UBXD1; little effects on the bindings to Hrd1, Png1 [ |
|
| |||
| R155S | N domain | IBMPFD | Enhanced bindings to Ufd1, Npl4, p47, and Ataxin 3 [ |
|
| |||
| R155C | N domain | IBMPFD and ALS | Increased bindings to Ufd1, Npl4, p47, Ataxin 3, and ubiquitylated substrates [ |
|
| |||
| R155P | N domain | IBMPFD | Increased bindings to Ufd1, Npl4, p47, and ubiquitylated substrates [ |
|
| |||
| R159G | N domain | ALS | Compromised degradation of ERAD substrates [ |
|
| |||
| R191Q | N-D1 linker | ALS and IBMPFD | Increased bindings to Ufd1, Npl4, p47, and ubiquitylated substrates [ |
|
| |||
| L198W | N-D1 linker | IBMPFD | Enhanced binding to ubiquitylated substrates; impaired ERAD [ |
|
| |||
| A232E | D1 domain | IBMPFD and ALS | Increased bindings to Ufd1, Npl4, p47, and ubiquitylated substrates; reduced bindings to CAV1, UBXD1 [ |
|
| |||
| T262A | D1 domain | IBMPFD | Impaired degradation of ERAD substrates [ |
|
| |||
| N387H | D1 domain | IBMPFD | Compromised ERAD; accumulation of ubiquitin containing inclusion [ |
|
| |||
| I27V, R95C, R97C, R97E, R155L, G157R, R159H, R159C | N domain | IBMPFD | |
|
| |||
| R95H, I151V | N domain | ALS | |
|
| |||
| I206F | N-D1 linker | IBMPFD | |
|
| |||
| R191G | N-D1 linker | ALS | |
|
| |||
| A439S, A439P | D1 domain | IBMPFD | |
|
| |||
| D592N | D2 domain | ALS | |